Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Friday, 31 July 2020

CLINUVEL Corporate Update

Previous Next

Download PDF
 
 
Friday, 31 July 2020

Appendix 4C – quarterly

CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C – Quarterly Cashflow Report and Activity Report for the period 01 April to 30 June 2020. All figures are rounded and reported in Australian dollars. Key Highlights: •  Cash receipts $10,403,000 over the quarter •  Net cash flow of $7,175,000 •  Cash and equivalents on hand increased […]

Download PDF
 
 
Thursday, 23 July 2020

Kommuniqué IV

Liebe Aktionäre, Freunde, Es stellt sich eine neue Welt dar, die darauf hinweist, dass das Virus nicht so leicht zu beseitigen sein wird. Waehrend wir es akzeptieren, einen Modus der Koexistenz zu finden, muessen wir für die mehr als 600.000 Menschen, die ihr Leben verloren haben und unzählige weitere, die von dieser Pandemie betroffen sind, […]

Download PDF
 
 
Wednesday, 22 July 2020

CLINUVEL Newsletter

Communiqué IV, 2020 – 22 July 2020 Dear shareholders, friends, As a new world presents itself indicating that the virus will not easily be eliminated as we are accepting to find a modus co-existentiae, albeit we need to pause for the more than 600,000 people who have lost their lives and countless more impacted by […]

Download PDF
 
 

Drug to be evaluated in patients with acute and systemic diseases Read more…

Download PDF
 
 

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and conditions of issue that the following unquoted performance rights have lapsed and forfeited […] Download PDF

Download PDF
 
 

Download PDF with speaker notes

Download PDF
 
 
Thursday, 21 May 2020

Kommuniqué III

Liebe Aktionäre, Freunde, Die außergewöhnlichen Zeiten, in denen wir leben, haben alle Kontinente beeinflusst. Jedes verlorene Leben war eins zu viel. Ich kann unseren italienischen medizinischen Kollegen, Patienten und Familien, die mit der Tragödie kämpfen, nicht genug Empathie entgegenbringen. Das Virus hat alle Ecken der Welt befallen und Italien nicht verschont, insbesondere die Regionen Lombardei, […]

Download PDF
 
 
 
Tuesday, 19 May 2020

CLINUVEL Newsletter

Dear shareholders, friends, The extraordinary times in which we are living have affected all continents. Each life lost has been one too many. I cannot express enough empathy to our Italian medical colleagues, patients and families battling it out with the tragedy. The virus has affected all corners of the world and has not spared […]

Download PDF
 
 
Friday, 08 May 2020

Chair Letter to Shareholders

Fellow shareholders, In my March letter I wished all good health during uncertain times. It is now clear the extent of damage COVID-19 has caused and will cause for many years in the future. I want to again share my thoughts on the long-term view of CLINUVEL, and how the business was set up to […]

Download PDF
 
 
Wednesday, 06 May 2020

过度曝光

With thanks to Andrea Minoglio we are able to share a copy of his intimate EPP documentary Overexposed with Mandarin subtitles. What’s your life like when your skin, like an ultra-sensitive film, gets burned as soon as you expose it to the slightest amount of light? Using a series of interviews and stories, included that […]

Download PDF
 
 

EXECUTIVE SUMMARY CLINUVEL, FDA and global vitiligo experts attended FDA meeting on 29 April Type C Meeting followed up with further amendments to CUV104 clinical study protocol CLINUVEL PHARMACEUTICALS LTD today confirmed that it attended a Type C meeting on 29 April with the US Food and Drug Administration (FDA) and global clinical experts in […]

Download PDF
 
 
Tuesday, 28 April 2020

Appendix 4C

  EXECUTIVE SUMMARY ACTIVITY REPORT QUARTER ENDING 31 MARCH 2020  Key Activity Highlights: Continued supply of SCENESSE® in Europe  SCENESSE® launch in USA following Prior Authorization by US insurers Expansion of in-house R&D capabilities, Singaporean government provides financial incentives Throughout the quarter CLINUVEL has continued to focus on expanding its business activities during a time […]

Download PDF
 
Wednesday, 29 January 2020

CLINUVEL Kommuniqué I

Sehr geehrte Aktionärinnen und Aktionäre, liebe FreundeIm Namen des CLINUVEL-Ausschusses wünsche ich Ihnen allen ein gutes neues Jahr in der Hoffnung, dass es Ihnen Gesundheit und Wohlstand verleiht. Wir bedanken uns vielmals bei Stan McLiesh, …

Download PDF
 
Thursday, 16 January 2020

CLINUVEL Newsletter

Dear shareholders, friendsOn behalf of the CLINUVEL Board, I wish you all a good new year in the hope that it confers you with good health and prosperity, in that particular sequence. We thank and …

Download PDF
 
Thursday, 05 December 2019

Appendix 3B

 New issue announcement, application for quotation of additional securities and agreement. 

Download PDF
 
Monday, 02 December 2019

CEO Letter

Dear shareholders, On 8 October 2019, CLINUVEL obtained its first and historic US Food and Drug Administration (FDA) approval, some 39 years since the afamelanotide technology was first discovered in a university laboratory. On this day …

Download PDF
 

Dearest Shareholders, As the incoming Chair of the Company, in short letters I will try to provide you with updates and inform you about our business.[...]

Download PDF
 

 CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair …

Download PDF
 
Thursday, 17 October 2019

CLINUVEL Newsletter

  In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the …

Download PDF
 
Tuesday, 15 October 2019

Chair Letter to Shareholders

  Dear All, In my career in life sciences, I have served on public Boards, was part of the management team that led CSL to its position and oversaw several executive transitions in our beloved Company, first …

Download PDF
 
Tuesday, 20 August 2019

CLINUVEL Newsletter - August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. [...]

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF